Ycanth - Drug Monograph

Introduction

Ycanth (cantharidin 0.7% topical solution) is a vesicant agent approved by the U.S. Food and Drug Administration for the topical treatment of molluscum contagiosum in adult and pediatric patients. It is applied by a healthcare professional directly to individual lesions, where it induces a controlled intraepidermal blister that helps clear the underlying viral infection. Ycanth represents the first FDA-approved drug therapy for molluscum contagiosum, a condition historically managed with watchful waiting, in-office curettage, cryotherapy, or cantharidin compounded by pharmacies.

Drug Class and Overview

• Drug class: Topical vesicant / topical blistering agent (cantharidin derivative preparation).
• Related/legacy agents: Compounded topical cantharidin preparations have been used off-label in dermatology for decades for molluscum contagiosum and, less commonly, for verruca vulgaris.
• Distinguishing features: Ycanth is a standardized, FDA-approved, single-use topical solution containing 0.7% cantharidin with a defined application protocol intended to minimize dosing variability, accidental exposure, and household transmission seen with traditional extemporaneous compounding.

Mechanism of Action

Cantharidin is a natural terpenoid (cantharide) that acts as a potent acantholytic agent. After topical application and occlusion, cantharidin is absorbed into the epidermis, where it disrupts desmosomal attachments between keratinocytes by interfering with desmoglein-1–mediated cell-cell adhesion. This results in intraepidermal (intraepidermolytic) vesiculation, with the blister roof formed by the stratum granulosum and the floor by the basal layer. The blister lifts infected keratinocytes and triggers a localized inflammatory response, which is thought to promote clearance of molluscum contagiosum virus–infected cells and host immune recognition of the virus.

Indications

• Topical treatment of molluscum contagiosum in adult and pediatric patients (FDA-approved indication).

Dosage and Administration

• Route: Topical cutaneous application only; must be applied by a healthcare professional. Not for self-administration or caregiver application.
• Preparation: Single-dose applicator containing 0.7% cantharidin topical solution.
• Application technique:
• A small amount of solution is applied with a precision applicator tip directly onto each individual lesion, avoiding surrounding healthy skin.
• The treated area is allowed to dry (approximately 2–5 minutes), then may be covered with a non-porous dressing or tape to enhance penetration and limit transfer.
• The dressing/cover is typically removed after approximately 24 hours, after which the lesion is washed with soap and water.
• Treatment course: Repeat applications are generally performed every 3 weeks as needed, up to a maximum of 4 total applications per lesion (per FDA labeling). Clinical judgment should guide further therapy beyond labeled recommendations.
• Special populations:
• Pediatric patients (≥2 years): Approved; dosing is the same as adults (per-lesion application).
• Geriatric patients: No specific dosage adjustment is specified; apply caution given thinner skin and greater risk of irritation.
• Pregnancy and lactation: Systemic absorption of topical cantharidin is minimal, but there are no well-controlled studies; use only if clearly needed.
• Renal/hepatic impairment: No systemic exposure–based dose adjustments are required because systemic absorption following proper topical use is negligible.

Pharmacokinetics

• Absorption: Following topical application with appropriate occlusion, cantharidin is absorbed into the epidermis. Systemic exposure following proper use is very limited.
• Metabolism: No formal human in vivo metabolism data are available. Cantharidin is a small terpenoid; any systemic absorption would be expected to undergo hepatic metabolism, though specific CYP enzyme pathways have not been characterized in clinical studies.
• Elimination: Detailed human pharmacokinetic data, including urinary excretion patterns, are not established in published FDA labeling. Systemic exposure after labeled use is expected to be low.
• Half-life: Not well characterized in humans because systemic concentrations after appropriate topical application are generally below standard quantification limits.

Contraindications

• Known hypersensitivity to cantharidin or any component of the formulation.

Warnings and Precautions

• Eye exposure: Cantharidin is a severe eye irritant; severe ocular injury, including corneal ulceration, has been reported from accidental transfer. Patients must avoid touching the application site, and healthcare professionals must take measures to prevent accidental transfer to the eyes. If eye contact occurs, flush immediately with water for at least 15 minutes and seek ophthalmologic evaluation.
• Application-site reactions: Expected pharmacologic effects include erythema, vesiculation, blistering, pruritus, pain, crusting, scabbing, and possible post-inflammatory hyper- or hypopigmentation or scarring. Lesions on thin-skin areas (face, axillae, groin) and mucosal surfaces are at higher risk of severe blistering.
• Secondary infection: Disruption of the skin barrier may predispose to bacterial superinfection; monitor for signs of cellulitis or impetigo.
• Accidental ingestion / systemic toxicity: Cantharidin is highly toxic if ingested orally and can cause severe gastrointestinal hemorrhage, renal tubular necrosis, and death. Oral ingestion must be avoided; appropriate disposal of unused solution and contaminated applicators is required.
• Avoid application to: Mucous membranes, eyes, and near the eyes; broken, inflamed, or infected skin; and large surface areas.

Drug Interactions

• Drug–drug interactions: No clinically significant systemic drug interactions are expected with appropriate topical use because systemic absorption is minimal.
• Drug–skin interactions: Concurrent application of other topical products (e.g., retinoids, benzoyl peroxide, corticosteroids, topical anesthetics) at the same site may increase skin irritation, vesiculation, or systemic absorption and should be avoided until the area is healed.
• Management note: Counsel patients and caregivers to avoid applying other topical products to treated lesions until the blister and crust have resolved.

Adverse Effects

Common (expected application-site reactions):

• Vesiculation, blistering, erythema
• Application-site pain, pruritus, burning
• Scabbing, crusting, erosions
• Post-inflammatory hyperpigmentation or hypopigmentation

Less common:

• Secondary bacterial skin infection
• Erosion or ulceration, particularly with over-application or application to thin skin
• Scarring

Serious / rare:

• Severe ocular injury from accidental transfer
• Severe blistering or chemical burn if misapplied to large areas or normal skin
• Systemic toxicity if ingested (nausea, hematemesis, abdominal pain, hematuria, renal injury, dysrhythmias, shock)

Monitoring Parameters

• At each visit: Inspection of treated lesions for blister formation, crusting, and resolution; assessment for secondary infection; documentation of any pigmentary changes or scarring.
• Safety monitoring: Patient/caregiver ability to keep the area dry and avoid touching or transferring the medication.
• Lab monitoring: No routine laboratory monitoring is required for appropriate topical use.
• Follow-up interval: Re-evaluate approximately every 3 weeks for repeat application as clinically indicated.

Patient Education

• Do not touch, scratch, or pick the treated lesions; keep the area clean and dry.
• The treated lesion typically forms a small blister within hours to a day; this is expected and part of the treatment effect.
• Avoid applying any other topical products (lotions, ointments, sunscreen, cosmetics) to the treated area until fully healed.
• Wash hands thoroughly after bathing or changing dressings; avoid transferring the medication to eyes or mucous membranes.
• If a blister becomes very painful, develops pus, or is accompanied by spreading redness or fever, contact a clinician.
• Keep scheduled follow-up appointments; do not attempt to self-apply the medication at home.

Clinical Pearls

• Ycanth is the first FDA-approved drug for molluscum contagiosum, standardizing a therapy previously reliant on compounded cantharidin.
• Correct application technique — small drop, lesion only, allow to dry, then occlude — is critical to efficacy and to minimizing transfer to normal skin or eyes.
• The mechanism is purely mechanical/acantholytic (desmosomal disruption), not antiviral; clinical efficacy derives from immune recognition of virus-laden cells after blister formation.
• No systemic monitoring is needed because systemic absorption is negligible when used as labeled — the safety profile is dominated by local skin and eye risks rather than systemic toxicity.
• For lesions near the eyes, eyelids, or mucosal surfaces, clinicians should consider alternative therapies due to risk of severe ocular injury from accidental transfer.
• Household members should be counseled to avoid contact with the patient's treated skin and any occlusive dressings to prevent inadvertent exposure.

References

1. Verrica Pharmaceuticals. Ycanth (cantharidin) topical solution 0.7% Prescribing Information. U.S. Food and Drug Administration, 2023.
2. U.S. Food and Drug Administration. FDA Approves First Drug for the Treatment of Molluscum Contagiosum (Press Release). FDA, 2023.
3. American Academy of Dermatology Association. Molluscum Contagiosum: Diagnosis and Treatment (Patient and Clinician Resource). AAD, current guidelines.
4. Centers for Disease Control and Prevention. Molluscum Contagiosum: Clinical Overview and Transmission. CDC.
5. World Health Organization. Skin-Related Neglected Tropical Diseases — Molluscum Contagiosum Fact Sheet. WHO.
6. Goldsmith LA, Katz SI, Gilchrest BA, et al., eds. Fitzpatrick's Dermatology in General Medicine (Standard reference for mechanism and management of molluscum contagiosum).
7. Wolverton SE, ed. Comprehensive Dermatologic Drug Therapy (Standard reference for topical cantharidin pharmacology and vesicant therapy).
8. DiPiro JT, Yee GC, Posey LM, et al., eds. Pharmacotherapy: A Pathophysiologic Approach (Reference for topical drug pharmacokinetics and dermatologic therapeutics).
9. Lexicomp Online. Cantharidin (topical) — Drug Information Monograph. Wolters Kluwer Clinical Drug Information (accessed for standard clinical reference).
10. National Library of Medicine. Cantharidin compound summary — mechanism and toxicology profile. PubChem / National Center for Biotechnology Information.